The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

49 th Annual Meeting and ToxExpo Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). KEY WORD INDEX 1, 1-Dichloroethylene..................... 1565 1, 6-Hexamethylene diamine......... 1328, 1864 1-bromohexane............................... 1562 1-Butyl-3-Methylimidazolium Chloride............................................ 297 1-Ethyl-3-Methylimidazolium Chloride............................................ 297 11b-HSD1....................................... 2084 1Ç3-b-glucan.................................... 737 2, 3, 7, 8-tetrachloro-dibenzo-p-dioxin (TCDD)......... 84, 384, 1033, 1195, 1198 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)..... 844, 1204, 1952, 2059, 2060 2, 5-hexanedione............................. 1267 2-butoxyethanol........................ 512, 679 2-DE................................................. 864 2-step................................................ 910 21-hydroxylase............................... 1379 28 day study.................................... 1155 3 dimensional in vitro model.......... 1486 3, 3-diindolylmethane....................... 128 3, 4-Dihydroxyphenylacetaldehyde........ 1274, 1275 3, 5, 6-trichloro-2-pyridinol............ 1865 3-caffeoyl-4-dicaffeoylquinic acid. 1774 3-caffeoyl; 4-dihydrocaffeoyl quinic acid................................................. 1763 3-D skin model................................... 62 3A4................................................. 1094 3D Model.......................................... 105 3D reconstructed epidermis.............. 307 3D tissue constructs.......................... 109 4-aminobiphenyl cytotoxicity........... 742 4-Chlorobiphenyl metabolites........ 1105 4-HNE....................................... 779, 787 4-hydroxynonenal................... 629, 1635 4EBP1............................................. 1667 8-hydroxy-2ʹ-deoxyguanosine.......... 966 a 2u -globulin..................................... 1924 Abandoned metal mine................... 1821 ABC transporter....................... 411, 622, 1621, 1626, 1749 ABCB1............................................. 358 Abcb6............................................. 1089 abrin................................................ 1153 absorption............................... 493, 1460 Abuse Potential............................... 1790 acai.................................................. 1135 ACB-PCR......................................... 331 acceptable daily intake (ADI)......... 1809 accumulation................................... 1245 acetaldehyde......................... 1112, 1919 Acetaminophen.... 744, 745, 1072, 1550, 1653, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139 acetanilides..................................... 1006 acetyl propionyl.............................. 1492 acetylcholine esterase....................... 899 Acetylcholinesterase...... 242, 434, 1237, 1241, 1242, 1243, 1894 acetylcholinesterase reactivator........ 335 aCGH................................................ 692 Acorus calamus.............................. 1131 Acrolein...................... 1166, 1764, 2018 acrylamide.......... 713, 1029, 1289, 1847 acrylic monomer............................. 1182 acrylonitrile..................... 526, 771, 1848 Actin............................................... 2169 action potential............................... 1753 acute.................................................. 439 acute inhalation..................... 1012, 1793 Acute isotonic volume overload..... 1736 Acute Kidney Injury......................... 806 acute lung injury............................... 597 acute renal failure............................. 319 acute systemic toxicity..................... 199 acute toxicity...... 185, 1131, 1917, 2075 adaptation....................................... 1449 additivity to backgrond....................... 36 additivity-to-background.................... 40 adduct............................................. 1289 Adenia cissampeloides..................... 423 ADHD............................................... 166 adipocyte........................................... 220 Adjuvant......................................... 1372 ADME.......................... 557, 1402, 1563 ADME-related genes...................... 1648 adrenal.................................. 1069, 1379 Adriamycin....................... 634, 722, 723 adult disease.................................... 1431 Adverse drug reactions..................... 317 adverse outcome pathway..... 1445, 1446 aerosol exposure system................. 1515 AFB1-Lysine.................................. 1457 affymetrix gene array...................... 1709 Aflatoxin............................... 1457, 1458 aflatoxin B1... 444, 445, 446, 680, 1160, 1161 aflatoxin B1-lysine adduct.............. 1163 aflatoxin B2...................................... 444 Aflatoxins......................................... 464 age..................................................... 340 age-dependent pharmacokinetics.....1592, 1911 age-specific..................................... 1947 agglomeration................................... 279 aging...................... 75, 916, 1247, 1524, 1616, 1644, 2011, 2012, 2013, 2015 Aging and evironmental health....... 2010 Ah Receptor.145, 539, 1200, 1206, 1534 AHA................................................. 692 AHR............................. 72, 89, 239, 240, 386, 522, 596, 663, 861, 1197, 1205, 1207, 1208, 1209, 1531, 1536, 1537, 1538, 1539, 1949, 2058, 2167, 2191 AhR ligands........................................ 76 AIDS............................................... 1119 air pollutants......................... 1856, 2015 air pollution..... 24, 718, 736, 776, 1496, 1505, 1510, 1520 Air pollution metals........................ 1560 air quality........................................ 1801 air toxicants.................................... 1504 Airborne PCBs.................................. 237 Airway hyper-responsiveness.......... 670, 1886 airway toxicity.................................. 470 AKR................................................ 1622 Akt.................................................. 1635 alachlor............................................. 509 Albendazole...................................... 404 alcohol........ 786, 787, 1599, 1632, 1633 Alcoholic Cardiomyopathy............ 1747 Alcoholic liver disease........... 907, 1358, 1631 Alcoholic steatosis.......................... 1765 aldehyde.......................................... 1687 aldehyde dehydrogenase........... 214, 595 aldehydes...................... 701, 2016, 2018 ALDH2................................... 359, 1108 aldo keto reductase........................... 452 aldosterone...................................... 1364 alginate........................................... 1964 algorithm........................................... 880 ALK5.............................................. 1724 Alkylaniline...................................... 696 alkylation............................................ 67 allegic inflammation......................... 726 allergic contact dermatitis........ 300, 303, 1789, 1807, 1870 allergic sensitization......................... 305 allergy................... 296, 298, 1302, 2180 alpha class......................................... 446 ALS/PDC.......................................... 167 ALT....................... 58, 1072, 1307, 1309 altered gravity................................. 1126 altered hepatic foci........................... 134 alternative....................................... 1412 alternative activation......................... 744 alternative medicine........................ 1529 Alternative Methods........ 474, 479, 485, 486, 501, 1408, 1808, 2218, 2220 Alternative model............................. 464 alternative model organism............... 461 alternative splicing................ 1346, 1648 Alternative Test Methods.................. 170 alternatively spliced variants............ 214 alternatives...................................... 1415 Alzheimer’s disease............. 1100, 1295, 1373, 1615 Alzheimer’s disease........................ 1283 Ambient Particulate Matter.... 1473, 2183 Ames Test......................................... 698 AMH................................................. 387 aminoglycoside............................... 1313 amiodarone............................. 750, 1229 Amphetamines................................ 1955 amphibole....................................... 1476 AMPK............................................. 1765 analysis........................................... 1849 analytics............................................ 258 anandamide..................................... 2153 anastrozole........................................ 431 anatomy and physiology....................... 8 Androgen........................................ 2084 androgen receptor........... 380, 425, 1470 androgens.......................................... 844 Aneugen.......................................... 1114 Aneurysm......................................... 866 Angiogenesis.......................... 758, 1766 Aniline...................................... 702, 777 animal............................................... 237 Animal - human extrapolation.......... 611 animal alternative............................. 110 Animal health................................... 588 animal model... 317, 449, 523, 591, 914, 929, 1742, 2124 animal models............. 43, 349, 607, 904 Animal models of human disease.... 611, 2056 Animal welfare................................. 920 animal-to-human extrapolation...... 2145 Animals........................................... 1891 ANIT................................................. 117 antagonism........................................ 339 anthocyanin..................................... 1759 anti-allergic activity.............. 1771, 1772 anti-allergic inflammation.............. 1561 anti-cancer........................................ 519 anti-drug antibodies.. 615, 617, 619, 620 anti-malarial...................................... 728 anti-tumor immunity....................... 1548 antiandrogenic................................ 1780 antiandrogens.................................... 562 antibacterial........................................ 95 antibiotics................................. 83, 1594 antibody.......................... 417, 616, 1201 anticancer agent...................... 530, 1779 Anticonvulsant.................................. 321 antidote............................................. 324 Antimicrobial.................................. 1901 antioxidant.................... 415, 1119, 1135 antioxidant enzymes....................... 1961 antioxidant response element........... 108 antiretroviral....................................... 95 Antiretrovirals................................. 1119 antisense......................................... 2082 Antiviral drug................................. 1582 anxiety.............................................. 465 Aorta................................................. 866 AP-1................................................ 1554 ApcMin mice.................................... 137 apoptosis.................. 163, 169, 179, 222, 516, 596, 731, 815, 821, 825, 828, 1165, 1211, 1216, 1221, 1222, 1223, 1233, 1288, 1471, 1676, 1695, 1781, 2036, 2144, 2174, 2195 apoptosis and necrosis.................... 2095 Apoptosis/cell survival..................... 990 applicability domain....................... 1789 aquatic pollutant............................. 1008 aquatic toxicology.......................... 2107 Aristolochic acid............................... 455 Aromatase............................. 1888, 1905 aromatic amines................................ 314 arsenate............................................. 949 arsenic.............. 119, 149, 492, 571, 572, 573, 574, 575, 576, 706, 749, 945, 946, 947, 950, 951, 952, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 1227, 1294, 1393, 1429, 1430, 1432, 1566, 1606, 1679, 1719, 1935, 1936, 1937, 1938, 1971, 1975 arsenic (+3 oxidation state) methyltransferase.............................. 948 Arsenic exposure............................ 1299 Arsenic trioxide................................ 531 arsenite............................................ 1971 aryl hydrocarbon receptor........ 295, 384, 1196, 1201, 1203, 1205, 1337, 1338, 1339, 1340, 1341, 1342, 1471, 1532, 1681, 1682 aryl hydrocarbon receptor (AHR)... 388, 398, 684, 1195, 1199, 1678, 2204 Aryl hyrdocarbon receptor (AhR).. 1198 Arylhydrocarbon receptor................ 399 As3MT.................................... 947, 1566 Asbestos....... 30, 34, 35, 312, 739, 1546, 1547, 1548, 1553, 1874, 1875, 1877 asbestosis.................................. 122, 933 Ascaris suum.................................... 729 Ascorbic acid............................ 515, 989 Asphalt.................................... 508, 1169 asthma......... 260, 759, 1517, 2020, 2197 astrocyte................................ 1239, 1244 astrocyte Mn..................................... 985 astrocytes.................... 1284, 1285, 2174 ATCA................................................ 337 atherosclerosis..... 575, 957, 1363, 1430, 1748 Athersclerosis................................. 1778 ATP synthase.................................... 946 atrazine................. 414, 831, 2087, 2092 Atropine.......................................... 1659 atropisomer..................................... 2062 attrition................................. 1081, 1377 atypical antipsychotics............ 584, 1063 auditory..................................... 155, 162 auditory startle................................ 2109 Autism.......................... 914, 1380, 1391 autoimmune.............................. 34, 1282 autoimmune disease................ 310, 1751 Autoimmunity................... 309, 311, 537 automation........................................ 116 autonomic....................................... 1501 autophagy...................... 265, 791, 1226, 227, 1228, 1269 axonal transport.............................. 1255 azoxymethane................................... 506 AZT.................................................. 785 Ab aggregation............................... 1283 B cell............................... 145, 632, 1997 B cell development......................... 1558 B cells................. 312, 1195, 1530, 1538 B-cell.............................................. 1060 B-Raf................................................ 518 BA homeostasis.............................. 1617 babyfood......................................... 1150 BACE1............................................ 1283 background additivity......................... 39 bacteria............................................. 667 bacterial infection........................... 2056 bacteriophages................................ 1162 Barker Hypothesis.......................... 1428 Basophils.......................................... 302 Bax........................................ 1218, 1219 Bayesian Analysis............................. 873 BBDR modeling............................. 1927 496 SOT 49 th Annual Meeting
Society of Toxicology 2010 Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). BBDR-HPT axis model.......... 894, 1383 BCOP................................ 100, 473, 475 BDE-47............................................. 643 BDNF..................................... 160, 1610 Beagle............................................. 2116 Beagle dog...................................... 1729 beagle dogs........................... 1810, 1979 BEAS-2B........................................ 1560 behavior................... 159, 174, 429, 465, 1036, 1392, 2028 behavioral development.................... 403 Behavioral testing............................. 166 Belatacept....................................... 2187 Benchmark Dose Approach.............. 841 Benfluralin........................................ 521 benzene.................... 123, 124, 127, 136, 363, 514, 527, 672, 780, 848, 1678, 1850, 1851, 1852 benzenearsenicals........................... 1101 Benzo(a)pyrene......... 137, 150, 535, 683 benzo[a]pyrene..... 451, 596, 1720, 2006 Benzo[a]pyrene (BaP).................... 1750 Bergamottin.................................... 1761 beta-amyloid, MAP kinase, Secretase......................................... 1297 beta-catenin..................................... 2157 beta-naphthoflavone....................... 2120 beta-secretase.................................. 2077 betulinic acid.................................. 2008 Bhas42 cells...................................... 511 bile.................................................... 898 bile acid synthesizing enzymes...... 1616 Bile acid transport............................. 624 Bile acids.......................... 57, 626, 1618 bile duct epithelial cells.................. 1958 Bile salt export pump................ 621, 623 bile salts............................................ 622 biliary epithelial cell....................... 1620 Binder............................................... 970 Bio-Plex............................................ 739 Bioaccessibility............................... 2165 bioaccumulation............................. 1836 bioactivation................. 458, 1096, 1405 bioaerosol......................................... 230 Bioanalytical................................... 1444 bioavailability...... 803, 972, 1936, 2164, 2166 biochemical..................................... 2214 Biochip Technology........................ 2075 biocides............................................. 397 Biocompatibility............................. 1187 Bioconcentration............................... 232 biodefense....................................... 1479 Biodegradation................................. 427 Biodistribution.................................. 843 bioenergetics....................................... 81 biofuel................................... 1167, 1172 Bioinformatics................ 210, 751, 2042 biological descriptor......................... 185 biological modeling........ 881, 900, 2076 biological pathway analysis.................. 1 biological pathway networks............ 410 biologically-based models.............. 1451 Biologicals...................................... 1577 biologicals, biologics............................ 2 Biologics..................... 1074, 1580, 1583 biomakers....................................... 2201 Biomarker............ 56, 57, 142, 579, 664, 807, 952, 1308, 1313, 1314, 1315, 1330, 1440, 1442, 1459, 1650, 1660, 1676, 1746, 1862, 1878, 1885, 2042, 2199 Biomarker and Biomonitoring.......... 320 Biomarker discovery......................... 534 biomarker of exposure.......... 1861, 2202 biomarker of neurotoxicity............. 1279 Biomarkers.......... 58, 59, 207, 578, 581, 751, 752, 1238, 1240, 1299, 1301, 1302, 1316, 1319, 1325, 1327, 1443, 1444, 1854, 1863, 2049, 2078, 2198, 2202 biomarkers and biomonitoring....... 1881 Biomaterials.................................... 2181 biomethylation.................................. 951 biomonitor...................................... 1878 biomonitoring........ 544, 560, 640, 1041, 1796, 1849, 1850, 1852, 1865, 1866, 1871, 1879, 1880, 1887, 2045 Biomonitoring Equivalents............... 544 Biopharmaceuticals.......................... 540 biosolids............................................ 435 bioterrorism.................................... 1152 biotherapeutics... 2, 615, 617, 620, 1434, 1435, 1436, 1437, 1438 Biotransformation..... 137, 232, 442, 449 Biotransformation/Cytochrome P450................................ 202, 452, 1093 Biphenyl......................................... 1920 birds.................................................. 439 birth defects...................................... 853 bispecific......................................... 1050 bisphenol........................................... 406 bisphenol A................ 78, 151, 249, 383, 460, 846, 859, 995, 1087, 1298, 1392, 1452, 1454, 1849, 2086 Bisphenol-A.............................. 416, 825 bivalves............................................. 988 Bladder................. 492, 955, 1300, 1826 bladder cancer.. 141, 531, 532, 953, 954, 958, 973 bladder chemical carcinogenesis...... 507 bladder tumor.................................. 1920 blood..................................... 2069, 2078 Blood biomarkers....... 1328, 1654, 2200 BLOOD BRAIN BARRIER.... 785, 1365 Blood Cadmium.............................. 1821 Blood Pressure........................ 666, 1727 blood-brain barrier......... 234, 281, 1210, 1254, 2163, 2187 Blue cohosh...................................... 687 BMAA.............................................. 167 BMP.................................................. 125 body weight.............................. 668, 918 bone........................................ 762, 2100 bone lead......................................... 1884 bone marrow................................... 1986 Bone marrow toxicity........... 1549, 1551 Boric Acid..................... 852, 1168, 2150 Botanical......................................... 2074 BOVINE............................... 1833, 1844 Bovine Corneal Opacity and Permeability Assay........................... 106 BP-DNA adducts.............................. 131 BPDE................................................ 133 brain............................................ 22, 608 brain development.......... 158, 855, 1604 brain metabolism............................ 1256 BrdU................................................. 178 Breast Cancer....... 120, 522, 1085, 1207, 1338, 1885, 1999, 2000, 2001, 2003, 2004 breast cancer cells........................... 2008 Breast milk........................................ 892 Brevetoxin.............................. 843, 2179 Bromate.......................... 811, 812, 1713 Brominated Flame Retardant......... 1542, 1570 brominated flame retardants........... 1574 Bromine............................................ 502 bromopropane................................... 772 bronchiolitis obliterans................... 1490 bsep..................... 623, 1051, 1062, 2122 Buprenorphine................................ 1575 Burn wound...................................... 483 butachlor........................................... 509 Butadiene........................................ 1882 Butyrylcholinesterase........... 1237, 1243 C-DIM............................................ 1225 c-FLIP............................................. 1664 C. elegans.... 460, 462, 464, 1286, 1287, 1465, 1832 C/EPB............................................... 675 C60................................................... 369 Ca/NFAT......................................... 1541 Cache Valley..................................... 287 Caco-2..................................... 790, 1101 Caco-2 cell proliferation................. 1102 cadmium................ 408, 424, 824, 1432, 1465, 1811, 1813, 1816, 1818, 1819, 1820, 1822, 1823, 1824, 1825, 1826, 1827, 1828, 1829, 2093 Cadmium (Cd).................................. 823 Caenorhabditis elegans.......... 184, 1607 Caenorhabditis elegans............ 82, 1262 Caenorhabditis elegans, silver nanoparticles, pmk-1...................... 1699 Caffeic acid phenethyl ester........... 1762 caffeine........................................... 1572 Calcineurin..................................... 1677 Calcium....... 177, 717, 1157, 1364, 1817 Calcium channel............................. 1232 calcium ions...................................... 525 calcium signaling............................ 1284 Calcium-independent phospholipase A2..................................................... 594 Calibration...................................... 1022 caloric restriction.................. 1134, 1623 Calpain............................................ 1250 CAM............................................... 1004 cAMP................................................ 518 cancer....................... 119, 763, 770, 945, 965, 967, 1321, 1368, 1369, 1370, 1407, 1675, 1826, 1942 Cancer mode of action.......... 1355, 1939 cancer risk....................................... 1937 Cancer Risk Assessment...... 1721, 1862, 1863, 1910, 1943, 1946 canine.............................................. 1309 Cannabinoids.......................... 140, 1525 CAPs............................................... 1505 Capsaicin........................................ 1773 CAR............................ 1206, 2147, 2155 CAR/PXR....................................... 2205 Carbamate............................. 1034, 1246 carbaryl................................... 895, 1247 carbon monoxide............................ 2117 carbon nanoparticles............. 2041, 2180 carbon nanotube................................ 788 carbon nanotubes...... 789, 796, 797, 800 carbon tetrachloride toxicity........... 2013 Carboxyl esterase............................ 1674 carboxylesterase............................. 1251 Carcinogenesis........... 56, 121, 523, 528, 650, 1344, 1345, 1347, 1348, 1433, 1668, 1713, 1791, 1921, 1947, 2034, 2170 Carcinogenesis Screening................. 698 carcinogenesis testing....................... 647 carcinogenic.................................... 1921 carcinogenicity........ 228, 508, 645, 646, 648, 649, 1082, 2005 carcinogenicity study................ 910, 911 carcinogenomics............................... 645 Cardiac arrhythmia......................... 1504 Cardiac Contractility........................ 600 Cardiac Ion Channels..................... 1732 Cardiac mitochondria..................... 1359 Cardiac Risk................................... 1732 Cardiac Safety................................ 1735 cardiac toxicity..................... 1420, 1725 Cardiac Toxicology......................... 1078 cardiolipin......................................... 598 cardiomyocyte................................ 1743 cardiomyocytes................................... 49 cardiomyopathy................................ 207 Cardiopulmonary.............................. 603 cardiotoxicity................... 79, 206, 1520, 1754, 1755 cardiovascular.................. 41, 42, 43, 44, 45, 441, 601, 606, 1068, 1308, 1500, 1503, 1505, 1736, 1751, 1752, 1971 Cardiovascular disease.......... 572, 1513, 1742, 1897, 2178 Cardiovascular safety pharm study............................................... 1752 Cardiovascular Toxicity........ 1376, 1744 Cardiovascular Toxicology............. 1726 career...................... 659, 660, 661, 1415 career development................... 658, 661 Career industry................................. 661 career planning................................. 657 caribou.............................................. 438 carosine........................................... 1136 Case Studies........................................ 11 Case Study........................................ 550 caspase............................................ 1211 caspase-3/7 activity......................... 1779 Caspase2........................................... 138 caspases.......................................... 2123 Catalase............................................. 863 Cataract........................................... 1643 cataractogenesis................................ 469 category.......................................... 1799 Cats................................................... 669 caveolin............................................... 61 CBER Perspective.......................... 1371 CCD-18Co........................................ 748 CCI Model...................................... 1048 CCl4.................................................. 889 CCO................................................ 1733 Cd-inducible MT transcription....... 1812 CD159a........................................... 1984 CD209............................................. 1074 CD40 Ligand.................................. 1525 CD40L............................................ 1533 CD86/CD54...................................... 301 CDODA-Me..................................... 532 CEES................................................ 353 Celiac Disease................................ 1156 Cell based assays............................ 2091 Cell biology.......................................... 6 cell biomechanics........................... 1858 Cell cycle.............................. 1199, 1951 Cell cycle arrest................................ 811 cell cycle protein............................. 1705 cell death...... 770, 827, 865, 1214, 1218, 1276, 1422, 1425 Cell Differentiation........................... 809 cell line........................................... 1405 cell microarray.................................. 468 cell migration.................................... 755 Cell Proliferation.............................. 132 cell signaling.................... 267, 576, 627, 1312, 1694 cell therapy......................................... 51 Cell transformation........... 116, 525, 678 cell viability...................................... 789 cell-based assays............................. 1666 cell-mediated immunity.................. 1991 Cells................................................ 1755 cellular function.................................... 4 Cellular Toxicity............................... 374 Cerebrocortical neuronal culture.... 1613 ceria nanoparticle............ 269, 277, 2069 cerium oxide................................... 1398 CFD.................................. 870, 871, 872 CFD-PBPK..................................... 1491 characterization......................... 284, 801 chelate............................................. 2172 chelators............................................ 378 Chem-informatics............................. 215 chemical.......................................... 1792 chemical allergy............................ 74, 75 chemical and biological weapons... 1848 chemical carcinogenesis................. 2004 chemical database............................. 882 chemical exposure..... 1175, 1192, 1848, 2210 chemical exposures........................... 655 chemical genetics............................ 2002 chemical hazard assessment............. 610 KEY WORD INDEX up-to-date information at www.toxicology.org 497
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIOLOGICAL PATHWAY ANALYSIS: AN I
Page 7 and 8:
11 ICH INITIATIVES FOR CONDUCTING P
Page 9 and 10:
models. Experimental approaches and
Page 11 and 12:
30 SILICA AND ASBESTOS IMMUNOTOXICI
Page 13 and 14:
40 NONCANCER TOXICITY POTENTIAL AT
Page 15 and 16:
ased products for patient administr
Page 17 and 18:
nase regulates Hsp27-induced reorga
Page 19 and 20:
exposure resulted in splenomegaly.
Page 21 and 22:
We investigated the effect of imati
Page 23 and 24:
well plate prevented free cell move
Page 25 and 26:
98 DERIVING SIGNATURES OF IN VIVO T
Page 27 and 28:
sulfate, cinnamic aldehyde, 2,4-din
Page 29 and 30:
The final product will be a system
Page 31 and 32:
mercially available STP brands by m
Page 33 and 34:
for six weeks, with 10 mg/kg azoxym
Page 35 and 36:
eceived RES post-TCDD exposure when
Page 37 and 38:
morigenesis. Knocking down of JARID
Page 39 and 40:
163 MICROPET IMAGING OF [18F]-DFNSH
Page 41 and 42:
These results are comparable to tha
Page 43 and 44:
activity as assessed by lever press
Page 45 and 46:
for measured physico-chemical param
Page 47 and 48:
199 DEVELOPMENT OF A MULTIPARAMETER
Page 49 and 50:
To cause PLD, a drug needs to enter
Page 51 and 52:
In contrast to the parent PBDEs and
Page 53 and 54:
transiently transfected HEK 293 cel
Page 55 and 56:
TCDD exposure, 24 h prior to a 20 %
Page 57 and 58:
244 NON-ADDITIVE EFFECTS OF PCB153
Page 59 and 60:
253 COMPARISON OF MIXTURE TOXICITY
Page 61 and 62:
two cerium oxide nanoparticles of v
Page 63 and 64:
271 SIZE-DEPENDENT EFFECTS OF TUNGS
Page 65 and 66:
adigms such as Tox 21 and Toxcast,
Page 67 and 68:
QDs with emission maximum at 800nm
Page 69 and 70:
Cleveland, while others were found
Page 71 and 72:
without the need of animal testing.
Page 73 and 74:
Conclusions: These results are cons
Page 75 and 76:
ing oxime reactivation and organoph
Page 77 and 78:
335 A NON-OXIME IMPROVES SURVIVAL I
Page 79 and 80:
alties suffer from permanent lung i
Page 81 and 82:
ies have established inflammatory b
Page 83 and 84:
363 GENETIC VARIATION IN ISOGENIC M
Page 85 and 86:
372 EVALUATING THE BIOLOGICAL INTER
Page 87 and 88:
dose of 1/20 LD50 (400 mg/kg.bwt) f
Page 89 and 90:
median CR-adjusted isoflavone conce
Page 91 and 92:
data indicate that AhR deletion pro
Page 93 and 94:
February 2006). The rabbit is one o
Page 95 and 96:
tal neurotoxicity (DNT) test (OECD
Page 97 and 98:
of selected microorganisms that are
Page 99 and 100:
BVI. Histopathological analysis was
Page 101 and 102:
446 MOLECULAR CLONING AND CHARACTER
Page 103 and 104:
portant in predicting risk. CYPs 1A
Page 105 and 106:
ats, which involves metabolic activ
Page 107 and 108:
473 BOVINE CORNEAL OPACITY AND PERM
Page 109 and 110:
482 TYPE III DEIODINASE (D3) IS PRO
Page 111 and 112:
tancy evaluation and ranking of bat
Page 113 and 114:
501 CHARACTERIZATION OF ESTERASE, G
Page 115 and 116:
510 REDOX CYCLING BY ENDOGENOUS 2-
Page 117 and 118:
prostate cancer cells. All 8 BEL de
Page 119 and 120:
metallic nickel nanoparticles. Acti
Page 121 and 122:
variety of more or less reactive ch
Page 123 and 124:
550 QUALIFICATION STRATEGIES-GENOTO
Page 125 and 126:
ferentiation, and 3) how mixtures o
Page 127 and 128:
572 LOW-CHRONIC ARSENIC EXPOSURE: E
Page 129 and 130:
582 IDENTIFICATION OF SENSITIVE URI
Page 131 and 132:
duced by the genetic outcross of fe
Page 133 and 134:
fects of new compounds are equally
Page 135 and 136:
acterize the current state of the s
Page 137 and 138:
620 CHARACTERIZATION OF POTENTIAL I
Page 139 and 140:
ways. Moreover, both MAP kinase and
Page 141 and 142:
641 POPS IN THE U.S. POPULATION AND
Page 143 and 144:
studies such as the NCS, consider h
Page 145 and 146:
the beginning of the academic caree
Page 147 and 148:
trophil infiltration, a significant
Page 149 and 150:
tactic response and optokinetic res
Page 151 and 152:
usually high spontaneous PIG-A MFs.
Page 153 and 154:
699 PROMUTAGEN ACTIVATION AND P450
Page 155 and 156:
oxodG in bone marrow, spleen, kidne
Page 157 and 158:
718 GENOTOXICITY OF ORGANIC EXTRACT
Page 159 and 160:
ment were 18.0 and 4.5 nM for BEAS-
Page 161 and 162:
strongest activation of nuclear fac
Page 163 and 164:
746 MACROPHAGE INHIBITORY CYTOKINE-
Page 165 and 166:
screening of cell migration. High-c
Page 167 and 168:
dase inhibition). In contrast, inhi
Page 169 and 170:
mice; the decrease was more pronoun
Page 171 and 172:
Markers of oxidative damage reached
Page 173 and 174:
793 PULMONARY RESPONSE, OXIDATIVE S
Page 175 and 176:
cilitate clinical and industrial ap
Page 177 and 178:
sion of p-p38, p-p53, p21 and cycli
Page 179 and 180:
821 KIDNEY INJURY MOLECULE-2 GENE D
Page 181 and 182:
commercial applications, and have b
Page 183 and 184:
developmental effects. The residual
Page 185 and 186:
strand breaks in an in vitro model
Page 187 and 188:
etate (immunotoxicity). 2,4-D was t
Page 189 and 190:
867 MELATONIN AMELIORATES CYCLOPHOS
Page 191 and 192:
pharmacokinetic (PBPK) models. Ten
Page 193 and 194:
of radiolabeled Mn (carrier-free 54
Page 195 and 196:
893 UNVEILING ASSOCIATIONS BETWEEN
Page 197 and 198:
using area under the concentration
Page 199 and 200:
912 COMMERCIAL FISH DIETS INDUCE VI
Page 201 and 202:
922 A STUDY OF PHOTOTOXICITY FOLLOW
Page 203 and 204:
from 0.1 to 2.9 g/L (saturated vapo
Page 205 and 206:
vasive method for assessing several
Page 207 and 208:
950 ARSENITE DOWN-REGULATES THE CAR
Page 209 and 210:
inflammatory signaling is altered b
Page 211 and 212:
treated wood. Seventy-five of 132 w
Page 213 and 214:
ergy homeostasis and raising levels
Page 215 and 216:
treated with mercury and then with
Page 217 and 218:
997 IN VIVO CORRELATES OF THE MANGA
Page 219 and 220:
of the panel. The panel was compris
Page 221 and 222:
sponse, location, and severity scor
Page 223 and 224:
tant source of n-3 fatty acids such
Page 225 and 226:
old for serious, irreversible or es
Page 227 and 228:
1045 SUBCHRONIC TOXICITY EVALUATION
Page 229 and 230:
sites collected 3 days after inject
Page 231 and 232:
1063 MOLECULAR MECHANISM OF OLANZAP
Page 233 and 234:
esponses, and can be available for
Page 235 and 236:
hence more physiologically relevant
Page 237 and 238:
thesized apoproteins, so we tested
Page 239 and 240:
vate CYP3A5 but could be released b
Page 241 and 242:
1108 STYRENE-INDUCED TOXIC EFFECTS
Page 243 and 244:
1118 THE PRESENCE OF DIETHYL FUMARA
Page 245 and 246:
zebrafish cells were first exposed
Page 247 and 248:
utene-1,4-dial, which has been show
Page 249 and 250:
groups, largely due to lower non-HD
Page 251 and 252:
Exposure to gluten in individuals w
Page 253 and 254:
contrast to VGSC activators such as
Page 255 and 256:
1175 70% HYDROFLUORIC ACID (HF) CUT
Page 257 and 258:
axis. An increase in hyaline drople
Page 259 and 260:
1194 esiRNA AND siRNA HIGH-THROUGHP
Page 261 and 262:
1203 ARYL HYDROCARBON RECEPTOR-DNA
Page 263 and 264:
permeability (calcein), mitochondri
Page 265 and 266:
olytic caspase activation, caspase-
Page 267 and 268:
teristics of a human T-type voltage
Page 269 and 270:
80% of the activity from the yellow
Page 271 and 272:
1251 DEVELOPMENTAL EXPOSURE TO DELT
Page 273 and 274:
1260 MANEB ENHANCES MPP + -INDUCED
Page 275 and 276:
demonstrated by knockdown of beclin
Page 277 and 278:
1278 PINK1 AND MITOCHONDRIAL DYNAMI
Page 279 and 280:
treatment for number of live worms.
Page 281 and 282:
1297 INVESTIGATION OF THE NEUROTOXI
Page 283 and 284:
1306 DEVELOPMENT OF AN IN VITRO ASS
Page 285 and 286:
1315 EVALUATION OF 3- AND 1-METHYLH
Page 287 and 288:
prior to kainic acid-induced seizur
Page 289 and 290:
1334 AFFECT OF GENETIC VARIATION ON
Page 291 and 292:
1346 THE OTHER WORLD OF THE TRANSCR
Page 293 and 294:
strate, leading to excess microvesi
Page 295 and 296:
1368 OVERVIEW OF THERAPEUTIC VACCIN
Page 297 and 298:
to a bovine adrenal cortical epithe
Page 299 and 300:
DOTC had no effects. These results
Page 301 and 302:
1398 PULMONARY TOXICITY OF CERIUM D
Page 303 and 304:
PPARα, LXR, ER, AR and AhR activit
Page 305 and 306:
1417 MECHANISM OF GENDER-DIVERGENT
Page 307 and 308:
els, they disrupt homeostatic contr
Page 309 and 310:
were to characterize exposure of th
Page 311 and 312:
1448 ADVERSE OUTCOME PATHWAYS AND E
Page 313 and 314:
the level in urine was 25% of the m
Page 315 and 316:
1;akt-2 double mutant and pdk-1 mut
Page 317 and 318:
jury effects when compared to contr
Page 319 and 320:
tude than equivalent oral doses. Af
Page 321 and 322:
cells; and increased iNOS and MCP-1
Page 323 and 324:
B6.Cg-Kit W-sh mice. These findings
Page 325 and 326:
1511 STATIN-TREATMENT EFFECTIVELY R
Page 327 and 328:
1520 EFFECT OF INHALATION EXPOSURE
Page 329 and 330:
numbers of IFN-γ producing cells w
Page 331 and 332:
These data indicate that TCDD treat
Page 333 and 334:
esponse to allogenic cells, where P
Page 335 and 336:
larly suppressed LPS-induced TNF-α
Page 337 and 338:
1565 INFLUENCE OF EXPOSURE ROUTE AN
Page 339 and 340:
veloping animals to adverse effects
Page 341 and 342:
the observed CL values were 0.07 L/
Page 343 and 344:
which is most relevant for potentia
Page 345 and 346:
tive impairment, suggesting that ox
Page 347 and 348:
1611 AN IN VITRO METABOLOMICS APPRO
Page 349 and 350:
Expression of the β6 integrin (Itg
Page 351 and 352:
ats (10 μg/kg TCDD). Here we repor
Page 353 and 354:
at liver slices and how the metabon
Page 355 and 356:
with gender differences in AUC and
Page 357 and 358:
oxetine (30 mg/kg reduced to 15 mg/
Page 359 and 360:
eleased from necrotic cells where i
Page 361 and 362:
plants, they are present in surface
Page 363 and 364:
ferentiation (quantitative in-cell
Page 365 and 366:
control for macrophage activation).
Page 367 and 368:
to 0.5μg/ml. Minimal inhibitory co
Page 369 and 370:
lines tested. Given that dex and AT
Page 371 and 372:
tion in the absence of an immune re
Page 373 and 374:
treated rats had lower calcium load
Page 375 and 376:
1740 PROFILING COMPOUNDS WITH CARDI
Page 377 and 378:
dothelial cells confirmed caveolin-
Page 379 and 380:
1758 GINKGO BILOBA EXTRACT INDUCES
Page 381 and 382:
arin-induced suppression of MDR1 ex
Page 383 and 384:
1780 ANTIANDROGENIC AND ANTIPROLIFE
Page 385 and 386:
included in the evaluation, most of
Page 387 and 388:
1799 GUIDANCE ON THE APPLICATION OF
Page 389 and 390:
However, substances with EC3 values
Page 391 and 392:
1816 CD-INDUCED EGFR TRANSACTIVATIO
Page 393 and 394:
1826 KERATIN 7 EXPRESSION IN INDEPE
Page 395 and 396:
centa were collected at the time of
Page 397 and 398:
1845 SYSTEMATIC SCREENING OF YEAST
Page 399 and 400:
underlying the development of co-mo
Page 401 and 402:
eing measured in experimental roden
Page 403 and 404:
ufactured in the US for more than 3
Page 405 and 406:
nine (N7-THB-Gua) and N7-hydroxyphe
Page 407 and 408:
1892 EFFECT OF LAMBDA-CYHALOTHRIN O
Page 409 and 410:
22 in Phase I. Antimicrobial pestic
Page 411 and 412:
kinetic and dynamic differences, an
Page 413 and 414:
iphenyl, saccharin and melamine was
Page 415 and 416:
1930 DEVELOPMENT OF A RELATIVE SOUR
Page 417 and 418:
1939 MODE OF ACTION FOR THE CANCER
Page 419 and 420:
human was about 1.5-fold lower (60
Page 421 and 422:
Disruption of BDEC integrity in alp
Page 423 and 424:
1968 A HUMAN HEPG2 LUCIFERASE ASSAY
Page 425 and 426:
in the offspring during tumor devel
Page 427 and 428:
een developed to investigate perfus
Page 429 and 430:
to 131.73 μg/mL for KLH-specific I
Page 431 and 432:
cell lines (ATCC) were cultured in
Page 433 and 434:
flammation and xenobiotic metabolis
Page 435 and 436:
vide many contributions: with its g
Page 437 and 438:
to-metal joint replacement. For exa
Page 439 and 440:
to be addressed or negotiated. Deci
Page 441 and 442:
especially with anti-TNF therapies.
Page 443 and 444:
genic line Tg(are:eGFP) was created
Page 445 and 446:
2074 COMPUTATIONAL ASSESSMENT OF TH
Page 447 and 448:
2084 INHIBITION OF 11β-HSD1 DECREA
Page 449 and 450: (T) and express several enzymes inv
Page 451 and 452: 2101 GENISTEIN MODULATION OF BLOOD
Page 453 and 454: males per group were dosed orally o
Page 455 and 456: ate the feasibility of assessing re
Page 457 and 458: changed. Hepatic protein carbonyl l
Page 459 and 460: sought to examine alterations in he
Page 461 and 462: 2147 A SINGLE AMINO ACID CONTROLS T
Page 463 and 464: Gstm7) was independent of both CAR
Page 465 and 466: ility of tungsten trioxide (WO3), t
Page 467 and 468: ured by real-time PCR array and rel
Page 469 and 470: glucose, and creatinine levels, and
Page 471 and 472: Several studies have reported suppr
Page 473 and 474: exposure between TCDD-exposed labor
Page 475 and 476: Furthermore, with increasing number
Page 477 and 478: Society of Toxicology 2010 Author I
Page 499: Society of Toxicology 2010 Author I
Page 503 and 504: Society of Toxicology 2010 Abstract
Page 513 and 514: 49 th Annual Meeting and ToxExpo A
Page 547 and 548: The Official Journal of the Society
show all

The Toxicologist - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?